RANCHO CORDOVA, Calif., Sept. 13 /PRNewswire/ — ThermoGenesis
Corp. (Nasdaq:
KOOLD), a leading supplier of innovative products and services
that process and store adult stem cells, said today that it has
been informed by NASDAQ that the Company is in compliance with all
NASDAQ listing standards, including the minimum price bid
requirement.
“We are pleased to have retained our presence on the NASDAQ
market,” said J. Melville Engle, Chief Executive Officer of
ThermoGenesis. “We finished fiscal 2010 in strong fashion and are
off to a solid start in fiscal 2011 as we execute on our strategies
to drive shareholder value,” he added.
About ThermoGenesis Corp.ThermoGenesis Corp. (www.thermogenesis.com) is a
leader in developing and manufacturing automated blood processing
systems and disposable products that enable the manufacture,
preservation and delivery of cell and tissue therapy products.
These include:
The BioArchive® System, an automated cryogenic device, is
used by cord blood stem cell banks in more than 30 countries for
cryopreserving and archiving cord blood stem cell units for
transplant. AXP® AutoXpress™ Platform (AXP), a
proprietary family of automated devices that includes the AXP and
the MXP™ MarrowXpress™ and companion sterile blood
processing disposables for harvesting stem cells in closed systems.
The AXP device is used for the processing of cord blood. The MXP is
used for the preparation of cell concentrates, including stem
cells, from bone marrow aspirates in the laboratory setting. The
Res-Q™ 60 BMC (Res-Q), a point-of-care system that is
designed for the preparation of cell concentrates, including stem
cells, from bone marrow aspirates. The CryoSeal® FS System, an
automated device and companion sterile blood processing disposable,
is use
‘/>”/>
SOURCE
